MAIA publishes ‘Positive Effects of THIO’ for potential SCLC treatment

MAIA Biotechnology announced the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer SCLC in the peer-reviewed scientific journal Nature Communications. The reported findings from the research, conducted in collaboration with the University of Texas Southwestern UTSW scientists, led by corresponding author Dr. Esra Akbay, demonstrate the immune-enhancing, metastasis-reducing effects of MAIA‘s telomere-targeting agent THIO 6TdG in several well-characterized in vitro and in vivo models of SCLC. “This publication highlights a rather unique dual mechanism of action for THIO as a first-in-clinic telomere-targeted anticancer agent for potential treatment of SCLC,” said Sergei M. Gryaznov, PhD., MAIA’s Chief Scientific Officer. “In addition to the direct and potent cancer cell depletion activity, the observed specific interferons stimulation, immune responses-enhancement, and metastasis-reducing effects of THIO provide solid scientific foundation for further advancement of this compound in clinical development.”